These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

545 related items for PubMed ID: 22553314

  • 1. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs.
    Bindels EM, Havermans M, Lugthart S, Erpelinck C, Wocjtowicz E, Krivtsov AV, Rombouts E, Armstrong SA, Taskesen E, Haanstra JR, Beverloo HB, Döhner H, Hudson WA, Kersey JH, Delwel R, Kumar AR.
    Blood; 2012 Jun 14; 119(24):5838-49. PubMed ID: 22553314
    [Abstract] [Full Text] [Related]

  • 2. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.
    Gröschel S, Schlenk RF, Engelmann J, Rockova V, Teleanu V, Kühn MW, Eiwen K, Erpelinck C, Havermans M, Lübbert M, Germing U, Schmidt-Wolf IG, Beverloo HB, Schuurhuis GJ, Ossenkoppele GJ, Schlegelberger B, Verdonck LF, Vellenga E, Verhoef G, Vandenberghe P, Pabst T, Bargetzi M, Krauter J, Ganser A, Valk PJ, Löwenberg B, Döhner K, Döhner H, Delwel R.
    J Clin Oncol; 2013 Jan 01; 31(1):95-103. PubMed ID: 23008312
    [Abstract] [Full Text] [Related]

  • 3. EVI1 overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia.
    Matsuo H, Kajihara M, Tomizawa D, Watanabe T, Saito AM, Fujimoto J, Horibe K, Kodama K, Tokumasu M, Itoh H, Nakayama H, Kinoshita A, Taga T, Tawa A, Taki T, Shiba N, Ohki K, Hayashi Y, Yamashita Y, Shimada A, Tanaka S, Adachi S.
    Haematologica; 2014 Nov 01; 99(11):e225-7. PubMed ID: 25015941
    [No Abstract] [Full Text] [Related]

  • 4. MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia.
    Jiang X, Huang H, Li Z, He C, Li Y, Chen P, Gurbuxani S, Arnovitz S, Hong GM, Price C, Ren H, Kunjamma RB, Neilly MB, Salat J, Wunderlich M, Slany RK, Zhang Y, Larson RA, Le Beau MM, Mulloy JC, Rowley JD, Chen J.
    Proc Natl Acad Sci U S A; 2012 Nov 20; 109(47):19397-402. PubMed ID: 23132946
    [Abstract] [Full Text] [Related]

  • 5. Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells.
    Arai S, Yoshimi A, Shimabe M, Ichikawa M, Nakagawa M, Imai Y, Goyama S, Kurokawa M.
    Blood; 2011 Jun 09; 117(23):6304-14. PubMed ID: 21190993
    [Abstract] [Full Text] [Related]

  • 6. ZNF521 Enhances MLL-AF9-Dependent Hematopoietic Stem Cell Transformation in Acute Myeloid Leukemias by Altering the Gene Expression Landscape.
    Chiarella E, Aloisio A, Scicchitano S, Todoerti K, Cosentino EG, Lico D, Neri A, Amodio N, Bond HM, Mesuraca M.
    Int J Mol Sci; 2021 Oct 06; 22(19):. PubMed ID: 34639154
    [Abstract] [Full Text] [Related]

  • 7. Incidence and characterization of MLL gene (11q23) rearrangements in acute myeloid leukemia M1 and M5.
    Poirel H, Rack K, Delabesse E, Radford-Weiss I, Troussard X, Debert C, Leboeuf D, Bastard C, Picard F, Veil-Buzyn A, Flandrin G, Bernard O, Macintyre E.
    Blood; 1996 Mar 15; 87(6):2496-505. PubMed ID: 8630416
    [Abstract] [Full Text] [Related]

  • 8. Improved classification of MLL-AF9-positive acute myeloid leukemia patients based on BRE and EVI1 expression.
    Noordermeer SM, Monteferrario D, Sanders MA, Bullinger L, Jansen JH, van der Reijden BA.
    Blood; 2012 May 03; 119(18):4335-7. PubMed ID: 22555662
    [No Abstract] [Full Text] [Related]

  • 9. Expression and prognostic significance of different mRNA 5'-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration.
    Haas K, Kundi M, Sperr WR, Esterbauer H, Ludwig WD, Ratei R, Koller E, Gruener H, Sauerland C, Fonatsch C, Valent P, Wieser R.
    Genes Chromosomes Cancer; 2008 Apr 03; 47(4):288-98. PubMed ID: 18181178
    [Abstract] [Full Text] [Related]

  • 10. High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group.
    Ho PA, Alonzo TA, Gerbing RB, Pollard JA, Hirsch B, Raimondi SC, Cooper T, Gamis AS, Meshinchi S.
    Br J Haematol; 2013 Sep 03; 162(5):670-7. PubMed ID: 23826732
    [Abstract] [Full Text] [Related]

  • 11. Cell of origin determines clinically relevant subtypes of MLL-rearranged AML.
    Krivtsov AV, Figueroa ME, Sinha AU, Stubbs MC, Feng Z, Valk PJ, Delwel R, Döhner K, Bullinger L, Kung AL, Melnick AM, Armstrong SA.
    Leukemia; 2013 Apr 03; 27(4):852-60. PubMed ID: 23235717
    [Abstract] [Full Text] [Related]

  • 12. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.
    Stubbs MC, Kim YM, Krivtsov AV, Wright RD, Feng Z, Agarwal J, Kung AL, Armstrong SA.
    Leukemia; 2008 Jan 03; 22(1):66-77. PubMed ID: 17851551
    [Abstract] [Full Text] [Related]

  • 13. EVI1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations.
    Lavallée VP, Gendron P, Lemieux S, D'Angelo G, Hébert J, Sauvageau G.
    Blood; 2015 Jan 01; 125(1):140-3. PubMed ID: 25331116
    [Abstract] [Full Text] [Related]

  • 14. MLL-AF9 and MLL-AF4 oncofusion proteins bind a distinct enhancer repertoire and target the RUNX1 program in 11q23 acute myeloid leukemia.
    Prange KHM, Mandoli A, Kuznetsova T, Wang SY, Sotoca AM, Marneth AE, van der Reijden BA, Stunnenberg HG, Martens JHA.
    Oncogene; 2017 Jun 08; 36(23):3346-3356. PubMed ID: 28114278
    [Abstract] [Full Text] [Related]

  • 15. ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.
    Germano G, Morello G, Aveic S, Pinazza M, Minuzzo S, Frasson C, Persano L, Bonvini P, Viola G, Bresolin S, Tregnago C, Paganin M, Pigazzi M, Indraccolo S, Basso G.
    Oncotarget; 2017 Apr 18; 8(16):26129-26141. PubMed ID: 28412727
    [Abstract] [Full Text] [Related]

  • 16. Essential role of PR-domain protein MDS1-EVI1 in MLL-AF9 leukemia.
    Zhang Y, Owens K, Hatem L, Glass CH, Karuppaiah K, Camargo F, Perkins AS.
    Blood; 2013 Oct 17; 122(16):2888-92. PubMed ID: 24021671
    [Abstract] [Full Text] [Related]

  • 17. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.
    Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, Valk PJ, van der Poel-van de Luytgaarde S, Hack R, Slater R, Smit EM, Beverloo HB, Verhoef G, Verdonck LF, Ossenkoppele GJ, Sonneveld P, de Greef GE, Löwenberg B, Delwel R.
    Blood; 2003 Feb 01; 101(3):837-45. PubMed ID: 12393383
    [Abstract] [Full Text] [Related]

  • 18. The AAA+ ATPase RUVBL2 is a critical mediator of MLL-AF9 oncogenesis.
    Osaki H, Walf-Vorderwülbecke V, Mangolini M, Zhao L, Horton SJ, Morrone G, Schuringa JJ, de Boer J, Williams O.
    Leukemia; 2013 Jul 01; 27(7):1461-8. PubMed ID: 23403462
    [Abstract] [Full Text] [Related]

  • 19. Aberrant expression of ecotropic viral integration site-1 in acute myeloid leukemia and acute lymphoblastic leukemia.
    Su G, Lian X, Tan D, Tao H, Liu H, Chen S, Yin H, Wu D, Yin B.
    Leuk Lymphoma; 2015 Feb 01; 56(2):472-9. PubMed ID: 24828867
    [Abstract] [Full Text] [Related]

  • 20. Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia.
    Huang H, Jiang X, Wang J, Li Y, Song CX, Chen P, Li S, Gurbuxani S, Arnovitz S, Wang Y, Weng H, Neilly MB, He C, Li Z, Chen J.
    Cancer Lett; 2016 Mar 28; 372(2):157-65. PubMed ID: 26791235
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.